查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1829857

2025年乳癌诊断全球市场报告

Breast Cancer Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，乳癌诊断市场呈现强劲成长势头，市场规模从2024年的46.8亿美元增加至2025年的50亿美元，复合年增长率达7.0%。这段历史性时期的成长可归因于意识提升宣传活动、筛检活动、乳房X光摄影检查、技术进步、基因检测以及多学科方法。

预计未来几年乳癌诊断市场规模将强劲成长，2029年将达到68.1亿美元，复合年增长率为8.0%。预测期内的成长可归因于个人化医疗、液态切片、3D乳房X光摄影（断层合成）、人工智慧和机器学习、远端医疗以及远距会诊。预测期内的主要趋势包括影像技术、个人化医疗、液态切片以及人工智慧和机器学习的进步。

乳癌是一种以乳房细胞不受控制地生长为特征的疾病，常导致肿块的形成。乳癌诊断设备旨在识别并确认乳房组织中是否存在癌性生长。

乳癌诊断的主要类别包括各种诊断方法，例如影像技术、切片检查、基因组检测、血液检测和其他相关方法。切片切片检查是从身体中取出组织或细胞样本进行后续实验室检测的过程，是乳癌病例中采用的主要诊断技术之一。这些诊断技术包括萤光原位杂合反应(FISH)、比较基因组杂合反应(CGH) 和免疫组织化学 (IHC)。乳癌可分为各种亚型，包括 BRCA乳癌、ER/PR乳癌、HER2乳癌、EGFR 突变和其他突变特异性乳癌。乳癌诊断进一步分为电离和非电离乳癌成像技术。这些诊断服务的最终用户包括医院和诊所、癌症研究中心、诊断实验室和门诊手术中心。

2025年春季，美国关税突然上调及其引发的贸易摩擦对医疗设备产业产生了重大影响，尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制涨价，製造商面临利润压力。监管挑战进一步加剧了形势，因为由于关税而更换供应商通常需要医疗设备重新认证，导致市场准入延迟。为此，企业正在透过双重采购关键零件、增加标准化产品的国内生产以及加快寻找更具成本效益的材料来降低风险。

本研究报告是商业研究公司 (The Business Research Company) 新报告系列的一部分，该系列提供乳癌诊断市场统计数据，例如全球市场规模、区域份额、乳癌诊断市场份额的竞争对手、详细的乳癌乳癌细分市场、市场趋势和商业机会，以及您在乳癌诊断行业取得成功所需的数据。本乳癌诊断市场研究报告对该行业的现状和未来趋势进行了详细分析，为您提供所需的一切观点。

未来五年8.0%的预测成长率，较我们先前对该市场的预测略有下降0.2%。这一下降主要源自于美国与其他国家之间关税的影响。这可能会透过对来自法国和英国等主要地区的免疫组织化学试剂和数位病理扫描仪征收关税直接影响美国，从而可能导致检测成本上升和治疗计划延迟。由于互惠关税以及贸易紧张局势和限制加剧对全球经济和贸易的负面影响，这种影响也将更加广泛地显现。

预计乳癌诊断市场的成长将受到乳癌发病率上升的推动。乳癌是最常见的癌症，每年影响约210万名女性，并导致女性癌症相关死亡人数最多，预计将推动对诊断设备的需求。早期发现对于改善乳癌预后和降低死亡率至关重要。例如，美国癌症协会于2022年1月报告称，2022年美国女性预计将新增287,850例浸润性乳癌病例和51,400例美国原位癌病例，其中43,250例乳癌相关死亡病例。因此，乳癌发生率的上升预计将推动乳癌诊断市场的发展。

政府针对乳癌的措施和资金有望促进乳癌诊断市场的成长。政府透过采取措施和提供财务支持，在推动乳癌研究、预防和治疗方面发挥着至关重要的作用。这些计画旨在提高人们对乳癌的认识，透过筛检和乳房X光摄影服务促进早期发现，并为贫困社区提供接受乳癌检测和治疗的财务支持。在 2022-23 年预算中，澳洲政府卫生署拨款 4,070 万美元，用于提高各种癌症检测和筛检服务的可近性，其中 970 万美元专门用于乳癌筛检。因此，政府的措施和资金筹措努力正在推动乳癌诊断市场向前发展。

乳癌诊断市场的关键趋势是技术的不断进步，从而推动了乳癌新诊断技术的发展。一项值得注意的创新是3D乳房X光摄影（也称为乳房断层合成），它从不同角度拍摄乳房的多张影像并建立3D模型。该领域技术创新的一个例子是印度健康科技公司Niramai于2022年9月推出的Thermalytix。 Thermalytix是一种自动化乳癌筛检和诊断工具，它结合了热成像和人工智慧，以增强乳癌的检测和诊断。

乳癌诊断市场的关键参与者正在积极开发基于人工智慧的尖端设备，旨在提高诊断准确性并推动市场收益。人工智慧乳癌诊断设备利用人工智慧演算法分析复杂的医疗数据并提供宝贵的诊断见解和建议。透过应用机器学习和资料处理技术，这些设备可以实现高度准确和高效的疾病识别。例如，英国生技公司 Digistain 于 2022 年 12 月推出了一款人工智慧乳癌诊断工具，准确率超过 99%。该技术经过临床研究和同行评审的检验，不仅可以加快诊断速度，还可以增强治疗决策。它有可能大幅减少等待时间、降低成本、实现个人化风险评估，并在某些情况下消除化疗的需要。透过应用机器学习和专有光学扫描，该设备可以识别传统方法经常忽略的复杂模式，提供经过大量患者样本验证的高度个人化风险评估。

2024年7月，美国医疗科技公司Hologic以3.1亿美元收购了Endomagnetics Ltd.。此次收购将整合Endomag创新的无线立体定位和淋巴追踪技术，并增强Hologic的乳房外科产品组合。总部位于英国的Endomagnetics Ltd.专注于先进的乳癌诊断解决方案，包括组织定位和淋巴追踪技术。

乳癌诊断市场的主要参与者包括雅培实验室、Myriad Genetics、Hologic、飞利浦、FUJIFILM Holdings、通用电气医疗、赛默飞世尔科技、西门子、NanoString Technologies、GammaMedica、Aurora Imaging Technology、Dillon Technologies、Exact Sciences、F. Hoffmann-La Roche、Aurora Imaging Technology、Dillon Technologies、Exact Sciences、F. Hoffmann-Top、Aurora、Moran Roche、Mr. GmbH、bioTheranostics Inc.、Bio-Rad Laboratories Inc.、Illumina Inc.、Biocept Inc.、Epigenomics AG、阿斯利康公司、Quest Diagnostics Incorporated、安捷伦科技公司、Cepheid、Guardant Health Inc.、Invitae Corporation、Natera Inc.、Geneo） Veracyte Inc.。

2024年，北美是乳癌诊断市场最大的地区。亚太地区是乳癌诊断产业的第二大地区。乳癌诊断市场报告涵盖亚太地区、西欧、东欧、北美、南美、中东和非洲。

宽频网路服务市场报告涵盖的国家包括澳洲、巴西、中国、法国、德国、印度、印尼、日本、俄罗斯、韩国、英国、美国、加拿大、义大利和西班牙

乳癌诊断市场涵盖用于乳癌诊断的分析仪、试剂和其他设备的销售。市场价值包括服务供应商销售或包含在其服务产品中的相关商品的价值。仅包括企业之间交易或销售给最终消费者的商品和服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球乳癌诊断：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球乳癌诊断市场：成长率分析
  • 全球乳癌诊断市场表现：规模与成长，2019-2024
  • 全球乳癌诊断市场预测：规模与成长，2024-2029年，2034年
  • 全球乳癌诊断：总目标市场（TAM）

第六章 市场细分

  • 全球乳癌诊断市场类型、表现及预测（2019-2024、2024-2029、2034）
  • 影像学
  • 切片检查
  • 基因组检测
  • 血液检查
  • 其他类型
  • 全球乳癌诊断市场（依技术、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 萤光原位杂合反应（FISH）
  • 比较基因组杂合反应（CGH）
  • 免疫组织化学（IHC）
  • 其他技术
  • 全球乳癌诊断市场（按癌症类型、表现和预测），2019-2024 年、2024-2029 年、2034 年
  • BRCA乳癌
  • ER和PR乳癌
  • HER2乳癌
  • 乳癌EGFR突变检测
  • 其他癌症类型
  • 全球乳癌诊断市场（按诊断类型、表现和预测），2019-2024 年、2024-2029 年、2034 年
  • 电离乳房成像技术
  • 非电离成像技术
  • 全球乳癌诊断市场（按最终用户、绩效和预测），2019-2024 年、2024-2029 年、2034 年
  • 医院和诊所
  • 癌症研究中心
  • 诊断实验室
  • 门诊手术中心
  • 全球乳癌诊断市场：按影像（类型）细分、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 乳房X光检查
  • 超音波影像
  • 磁振造影（MRI）
  • 正子断层扫描（PET）
  • 断层合成
  • 全球乳癌诊断市场：依切片检查类型、绩效及预测细分，2019-2024 年、2024-2029 年、2034 年
  • 针吸切片
  • 芯针切片
  • 细针抽吸切片检查（FNA）
  • 立体定位切片检查
  • 全球乳癌诊断市场：按基因组测试类型、表现和预测细分，2019-2024 年、2024-2029 年、2034 年
  • Oncotype DX
  • 妈妈印花
  • PAM50
  • BRCA1或2检测
  • 全球乳癌诊断市场：按血液检测类型、表现和预测细分，2019-2024 年、2024-2029 年、2034 年
  • 液态生物检体
  • 循环肿瘤DNA（ctDNA）检测
  • 循环性肿瘤细胞（CTC）检测
  • 全球乳癌诊断市场：按类型、其他、绩效和预测细分，2019-2024 年、2024-2029 年、2034 年
  • 荷尔蒙受体检测
  • HER2检测
  • 基因突变检测

第七章 区域和国家分析

  • 全球乳癌诊断市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球乳癌诊断市场：依国家、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章：西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章：俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 乳癌诊断市场：竞争格局
  • 乳癌诊断市场：公司简介
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Hologic Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Koninklijke Philips NV Overview, Products and Services, Strategy and Financial Analysis
    • Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • GE Healthcare
  • Thermo Fisher Scientific Inc.
  • Siemens AG
  • NanoString Technologies Inc.
  • Gamma Medica Inc.
  • Aurora Imaging Technology Inc.
  • Dilon Technologies Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Micrima Limited
  • Provista Diagnostics Inc.
  • Leica Biosystems Nussloch GmbH
  • bioTheranostics Inc.
  • Bio-Rad Laboratories Inc.
  • Illumina Inc.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029年乳癌诊断市场：提供新机会的国家
  • 2029年乳癌诊断市场：细分领域带来新机会
  • 2029年乳癌诊断市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r32425u

Breast cancer is a medical condition characterized by the uncontrolled proliferation of cells within the breast, often leading to the formation of lumps. Breast cancer diagnostic devices are designed for the purpose of identifying and confirming the presence of cancerous growth within the breast tissue.

Key categories within breast cancer diagnostics include various diagnostic methods such as imaging techniques, biopsies, genomic testing, blood tests, and other relevant approaches. Biopsy, a process involving the removal of tissue or cellular samples from the body for subsequent laboratory testing, is one of the primary diagnostic techniques employed in breast cancer cases. The technologies utilized for these diagnostic procedures encompass Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC) techniques, along with others. Breast cancer exhibits diverse types, including BRCA breast cancer, ER and PR breast cancer, HER2-positive breast cancer, EGFR mutation test breast cancer, and additional variants. Breast cancer diagnostics are further categorized into ionizing breast imaging technologies and non-ionizing imaging technologies. The end-users of these diagnostic services encompass hospitals and clinics, cancer research centers, diagnostic laboratories, as well as ambulatory surgical centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The breast cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides breast cancer diagnostics market statistics, including breast cancer diagnostics industry global market size, regional shares, competitors with a breast cancer diagnostics market share, detailed breast cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer diagnostics industry. This breast cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breast cancer diagnostics market size has grown strongly in recent years. It will grow from $4.68 billion in 2024 to $5 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to awareness and screening campaigns, mammography screening, technological advancements, genetic testing, multidisciplinary approach.

The breast cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $6.81 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to personalized medicine, liquid biopsies, 3d mammography (tomosynthesis), ai and machine learning, telemedicine and remote consultations. Major trends in the forecast period include advancements in imaging technologies, personalized medicine, liquid biopsies, ai and machine learning.

The forecast of 8.0% growth over the next five years indicates a slight reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through tariffs on immunohistochemistry reagents and digital pathology scanners, sourced from key regions such as France and the UK, which could lead to higher laboratory testing costs and potential delays in treatment planning.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the breast cancer diagnostics market is expected to be driven by the increasing incidence of breast cancer. With breast cancer being the most prevalent form of cancer, affecting approximately 2.1 million women annually and resulting in the highest number of cancer-related deaths among women, the demand for diagnostic equipment is set to rise. Early detection is paramount in improving the prognosis and reducing the mortality rate associated with breast cancer. For example, in January 2022, the American Cancer Society reported an estimated 287,850 new cases of invasive breast cancer and 51,400 cases of DCIS in women in the United States for 2022, with an expected 43,250 breast cancer-related fatalities. Hence, the escalating incidence of breast cancer is projected to fuel the breast cancer diagnostics market.

Government initiatives and funding for breast cancer are poised to contribute to the growth of the breast cancer diagnostics market. Government support, through initiatives and financial backing, plays a crucial role in advancing breast cancer research, prevention, and treatment. These programs aim to raise awareness, promote early detection through screening and mammography services, and provide financial aid for underserved communities undergoing breast cancer testing and treatment. In the budget for 2022-23, the Australian Government Department of Health allocated $40.7 million to improve the accessibility of testing and screening services for various cancer types, including a dedicated $9.7 million for breast cancer screening. Consequently, government initiatives and funding initiatives are propelling the breast cancer diagnostics market forward.

In the breast cancer diagnostics market, a significant trend is the continuous advancement in technology, which has led to the development of new diagnostic techniques for breast cancer. One notable innovation is 3D mammography, also known as breast tomosynthesis, which captures multiple images of the breast from various angles and constructs a 3-D model. An example of technological innovation in this field is the introduction of Thermalytix by Niramai, an Indian Health-Tech company, in September 2022. Thermalytix is an automated breast cancer screening and diagnostic tool that combines thermal imaging with artificial intelligence to enhance breast cancer detection and diagnosis.

Key players in the breast cancer diagnostics market are actively engaged in the development of cutting-edge AI-based devices designed to improve diagnostic accuracy and drive market revenues. AI breast cancer diagnostic devices leverage artificial intelligence algorithms to analyze complex medical data and offer valuable diagnostic insights and recommendations. By applying machine learning and data processing techniques, these devices can deliver highly accurate and efficient disease identification. For example, Digistain, a biotech company based in the United Kingdom, launched an AI breast cancer diagnostic tool in December 2022, boasting an accuracy rate of over 99%. This technology, validated through clinical studies and peer reviews, not only expedites diagnoses but also enhances treatment decisions. It holds the potential to significantly reduce waiting times, lower costs, and enable personalized risk assessment, potentially eliminating the need for chemotherapy in some cases. Through the application of machine learning and proprietary optical scans, this device can identify intricate patterns that traditional methods may overlook, providing highly personalized risk evaluations validated with a substantial patient sample.

In July 2024, Hologic Inc., a US-based healthcare technology company, acquired Endomagnetics Ltd. for $310 million. This acquisition allows Hologic to strengthen its breast surgery portfolio by integrating Endomag's innovative wireless localization and lymphatic tracing technologies. Endomagnetics Ltd., based in the UK, specializes in advanced breast cancer diagnostic solutions, including technologies for tissue localization and lymphatic tracing.

Major companies operating in the breast cancer diagnostics market include Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Epigenomics AG, AstraZeneca plc, Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

North America was the largest region in the breast cancer diagnostics market in 2024. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the broadband internet services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The breast cancer diagnostics market consists of sales of instruments such as analyzer, reagents and others that are used for the diagnosis of breast cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on breast cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for breast cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The breast cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Imaging; Biopsy; Genomic Tests; Blood Tests; Other Types
  • 2) By Technology: Fluorescent In Situ Hybridization (FISH); Comparative Genomic Hybridization (CGH); Immunohistochemical (IHC); Other Technologies
  • 3) By Cancer Type: BRCA Breast Cancer; ER And PR Breast Cancer; HER 2 Breast Cancer; EGFR Mutation Test Breast Cancer; Other Cancer Types
  • 4) By Diagnostic Type: Ionizing Breast Imaging Technologies; Non-ionizing Imaging Technologies
  • 5) By End Users: Hospitals And Clinics; Cancer Research Centers; Diagnostic Laboratories; Ambulatory Surgical Centers
  • Subsegments:
  • 1) By Imaging: Mammography; Ultrasound Imaging; Magnetic Resonance Imaging (MRI); Positron Emission Tomography (PET); Tomosynthesis
  • 2) By Biopsy: Needle Biopsy; Core Needle Biopsy; Fine Needle Aspiration Biopsy (FNA); Stereotactic Biopsy
  • 3) By Genomic Tests: Oncotype DX; MammaPrint; PAM50; BRCA1 Or 2 Testing
  • 4) By Blood Tests: Liquid Biopsy; Circulating Tumor DNA (ctDNA) Tests; Circulating Tumor Cells (CTCs) Tests
  • 5) By Other Types: Hormone Receptor Tests; HER2 Tests; Genetic Mutation Testing
  • Companies Mentioned: Abbott Laboratories; Myriad Genetics Inc.; Hologic Inc.; Koninklijke Philips N.V.; Fujifilm Holdings Corporation; GE Healthcare; Thermo Fisher Scientific Inc.; Siemens AG; NanoString Technologies Inc.; Gamma Medica Inc.; Aurora Imaging Technology Inc.; Dilon Technologies Inc.; Exact Sciences Corporation; F. Hoffmann-La Roche Ltd; Micrima Limited; Provista Diagnostics Inc.; Leica Biosystems Nussloch GmbH; bioTheranostics Inc.; Bio-Rad Laboratories Inc.; Illumina Inc.; Biocept Inc.; Epigenomics AG; AstraZeneca plc; Quest Diagnostics Incorporated; Agilent Technologies Inc.; Cepheid; Guardant Health Inc.; Invitae Corporation; Natera Inc.; NeoGenomics Laboratories Inc.; Oncocyte Corporation; PerkinElmer Inc.; Sysmex Corporation; Veracyte Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Breast Cancer Diagnostics Market Characteristics

3. Breast Cancer Diagnostics Market Trends And Strategies

4. Breast Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Breast Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Breast Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Breast Cancer Diagnostics Market Growth Rate Analysis
  • 5.4. Global Breast Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Breast Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Breast Cancer Diagnostics Total Addressable Market (TAM)

6. Breast Cancer Diagnostics Market Segmentation

  • 6.1. Global Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Imaging
  • Biopsy
  • Genomic Tests
  • Blood Tests
  • Other Types
  • 6.2. Global Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Fluorescent In Situ Hybridization (FISH)
  • Comparative Genomic Hybridization (CGH)
  • Immunohistochemical (IHC)
  • Other Technologies
  • 6.3. Global Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • BRCA Breast Cancer
  • ER And PR Breast Cancer
  • HER 2 Breast Cancer
  • EGFR Mutation Test Breast Cancer
  • Other Cancer Types
  • 6.4. Global Breast Cancer Diagnostics Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ionizing Breast Imaging Technologies
  • Non-ionizing Imaging Technologies
  • 6.5. Global Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals And Clinics
  • Cancer Research Centers
  • Diagnostic Laboratories
  • Ambulatory Surgical Centers
  • 6.6. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Imaging, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Mammography
  • Ultrasound Imaging
  • Magnetic Resonance Imaging (MRI)
  • Positron Emission Tomography (PET)
  • Tomosynthesis
  • 6.7. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Biopsy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Needle Biopsy
  • Core Needle Biopsy
  • Fine Needle Aspiration Biopsy (FNA)
  • Stereotactic Biopsy
  • 6.8. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Genomic Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncotype DX
  • MammaPrint
  • PAM50
  • BRCA1 Or 2 Testing
  • 6.9. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Blood Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Liquid Biopsy
  • Circulating Tumor DNA (ctDNA) Tests
  • Circulating Tumor Cells (CTCs) Tests
  • 6.10. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hormone Receptor Tests
  • HER2 Tests
  • Genetic Mutation Testing

7. Breast Cancer Diagnostics Market Regional And Country Analysis

  • 7.1. Global Breast Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Breast Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Breast Cancer Diagnostics Market

  • 8.1. Asia-Pacific Breast Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Breast Cancer Diagnostics Market

  • 9.1. China Breast Cancer Diagnostics Market Overview
  • 9.2. China Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Breast Cancer Diagnostics Market

  • 10.1. India Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Breast Cancer Diagnostics Market

  • 11.1. Japan Breast Cancer Diagnostics Market Overview
  • 11.2. Japan Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Breast Cancer Diagnostics Market

  • 12.1. Australia Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Breast Cancer Diagnostics Market

  • 13.1. Indonesia Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Breast Cancer Diagnostics Market

  • 14.1. South Korea Breast Cancer Diagnostics Market Overview
  • 14.2. South Korea Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Breast Cancer Diagnostics Market

  • 15.1. Western Europe Breast Cancer Diagnostics Market Overview
  • 15.2. Western Europe Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Breast Cancer Diagnostics Market

  • 16.1. UK Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Breast Cancer Diagnostics Market

  • 17.1. Germany Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Breast Cancer Diagnostics Market

  • 18.1. France Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Breast Cancer Diagnostics Market

  • 19.1. Italy Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Breast Cancer Diagnostics Market

  • 20.1. Spain Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Breast Cancer Diagnostics Market

  • 21.1. Eastern Europe Breast Cancer Diagnostics Market Overview
  • 21.2. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Breast Cancer Diagnostics Market

  • 22.1. Russia Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Breast Cancer Diagnostics Market

  • 23.1. North America Breast Cancer Diagnostics Market Overview
  • 23.2. North America Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Breast Cancer Diagnostics Market

  • 24.1. USA Breast Cancer Diagnostics Market Overview
  • 24.2. USA Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Breast Cancer Diagnostics Market

  • 25.1. Canada Breast Cancer Diagnostics Market Overview
  • 25.2. Canada Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Breast Cancer Diagnostics Market

  • 26.1. South America Breast Cancer Diagnostics Market Overview
  • 26.2. South America Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Breast Cancer Diagnostics Market

  • 27.1. Brazil Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Breast Cancer Diagnostics Market

  • 28.1. Middle East Breast Cancer Diagnostics Market Overview
  • 28.2. Middle East Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Breast Cancer Diagnostics Market

  • 29.1. Africa Breast Cancer Diagnostics Market Overview
  • 29.2. Africa Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Breast Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Breast Cancer Diagnostics Market Competitive Landscape
  • 30.2. Breast Cancer Diagnostics Market Company Profiles
    • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Hologic Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Koninklijke Philips N.V. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Breast Cancer Diagnostics Market Other Major And Innovative Companies

  • 31.1. GE Healthcare
  • 31.2. Thermo Fisher Scientific Inc.
  • 31.3. Siemens AG
  • 31.4. NanoString Technologies Inc.
  • 31.5. Gamma Medica Inc.
  • 31.6. Aurora Imaging Technology Inc.
  • 31.7. Dilon Technologies Inc.
  • 31.8. Exact Sciences Corporation
  • 31.9. F. Hoffmann-La Roche Ltd
  • 31.10. Micrima Limited
  • 31.11. Provista Diagnostics Inc.
  • 31.12. Leica Biosystems Nussloch GmbH
  • 31.13. bioTheranostics Inc.
  • 31.14. Bio-Rad Laboratories Inc.
  • 31.15. Illumina Inc.

32. Global Breast Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Breast Cancer Diagnostics Market

34. Recent Developments In The Breast Cancer Diagnostics Market

35. Breast Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 35.1 Breast Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Breast Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Breast Cancer Diagnostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer